i am not impressed, page-4

RR - You seem to be weak at calculations, but going by your past posts and lack of basic commonsense, I am not surprised.

See my calculatons:

Number of patients suitable for Cvac: 33,000 pa

Market Penetration would be atleat 20% consorvatively, as Cvac would be the best product on the market if approved.

Number of patients per year to be treated: 6,600

Now with all the money spent on the technology and more than 10 years of research why would the company make only $10,500 profit from each patient (as per your post). I believe profit margin would be in the range of 40% or minimum $20k per patient. If the sales price is conservatively $50k per patient, the profit would be $20,000 per patient. Please note that even if the cost of production is high, the company will expect to make atleast $20k per patient. That is a profit of $132 million per year (6,600 patients * 20k). With a Price Earnings Ratio of 10 years, we get a market cap of $1.3 billion. Then there could be the possibility of bigger market share, treatment of other cancers, etc.

Why do you think DNDN's cap went to $5 billion when sales expectations were solid. Cvac has no competition yet, its cost is lower than DNDN's as Cvac can be produced from blood taken at one time, Cvac is also expected to be more effective due to intra-dermal delivery.

You have also messed up the cap raise calculations (plucked $60 million from the air). If we need more capital after 2 years, so be it. If the SP is $1 because of ongoing good results, we can issue 60 million shares at $1 and dilution would be minimal (6%). If the SP is not high then there is no question of cap raise as this will be because Cvac may not be effective. The discussion is over. If Cvac is approved the market cap can go to unimaginable highs. And we will get some results before year end which will indicate whether we are on a winner. Based on today's discussions, I believe we are.

Brainy